title: Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.
abstract: The aim of this study was to investigate and compare the immunogenicity of liposome-forming, sustained release lipid implants containing either an alpha-galactosylceramide (alpha-GalCer) analogue, imiquimod or Quil-A (QA) as adjuvants. Ovalbumin (OVA) was used as a model antigen. Groups of C57Bl/6 mice were subcutaneously immunised with lipid implants containing one of the adjuvants, or inoculated with OVA in alum. The expansion of CD8+ and CD4+ transgenic T cells was analysed to assess the ability of these implants to stimulate cell-mediated immunity. In addition, the production of OVA-specific IgG antibodies was determined. QA-containing lipid implants were more efficient in the stimulation of CD8+ T cells and IgG antibodies than the two immunomodulators alpha-GalCer and imiquimod. These results suggest that, using this immunisationprotocol and dose of immunomodulators, QA was superior to imiquimod and alpha-GalCer.
authors.affiliation: School of Pharmacy, University of Otago, Dunedin, New Zealand.
authors.forename: J
authors.initials: J
authors.lastname: Myschik
authors.forename: W T
authors.initials: WT
authors.lastname: McBurney
authors.forename: T
authors.initials: T
authors.lastname: Hennessy
authors.forename: T
authors.initials: T
authors.lastname: Rades
authors.forename: S
authors.initials: S
authors.lastname: Hook
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000634:Aminoquinolines / Q000008:administration & dosage* / Q000276:immunology*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004343:Drug Implants; D000939:Epitopes; D005434:Flow Cytometry; D005699:Galactosylceramides / Q000008:administration & dosage* / Q000276:immunology*; D000077271:Imiquimod; D007114:Immunization; D007074:Immunoglobulin G / Q000276:immunology; D008055:Lipids; D051379:Mice; D008810:Mice, Inbred C57BL; D046529:Microscopy, Electron, Transmission; D030781:Organisms, Genetically Modified; D010047:Ovalbumin / Q000276:immunology; D062605:Quillaja Saponins; D012503:Saponins / Q000008:administration & dosage* / Q000276:immunology*; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004343:Drug Implants; D000939:Epitopes; D005699:Galactosylceramides; D007074:Immunoglobulin G; D008055:Lipids; D062605:Quillaja Saponins; D012503:Saponins; D014612:Vaccines; C493154:alpha-galactosylceramide; C046386:Quil A; D010047:Ovalbumin; D000077271:Imiquimod